Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

PAMELA D MOORE

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1598838435
CMS profile
118001
Location
PLANO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$38.13

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $38.13 1

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
SANOFI PASTEUR INC. $38.13 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

PAMELA D MOORE

NPI 1598838435 · CMS profile ID 118001

Allopathic & Osteopathic Physicians / Internal Medicine

PLANO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1598838435?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
PAMELA D MOORE, NPI 1598838435, CMS profile ID 118001. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1598838435?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). PAMELA D MOORE, NPI 1598838435, CMS profile ID 118001. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1598838435?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
PAMELA D MOORE, NPI 1598838435, CMS profile ID 118001, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1598838435?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $38.13 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
SANOFI PASTEUR INC. $38.1310/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044057601 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,374.14 113
PY2020 $293.54 19
PY2021 $266.59 11
PY2023 $38.13 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2023
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2023
Generated from
OP_DTL_GNRL_PGYR2023_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2024 Principal investigator $150.00 1
PY2023 Principal investigator $81,329.92 42
PY2022 Principal investigator $230,331.53 69
PY2021 Principal investigator $235,861.88 64
PY2020 Principal investigator $331,535.42 56
PY2019 Principal investigator $588,251.30 60

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

64 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $6,373.75 12/09/2021 Non-covered Recipient Entity
CLINRX RESEARCH LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792486363
Principal investigator 1 ABBVIE INC. $200.00 12/02/2021 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792485017
Principal investigator 1 ABBVIE INC. $400.00 12/02/2021 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792485019
Principal investigator 1 ABBVIE INC. $7,119.95 12/02/2021 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792485021
Principal investigator 1 ABBVIE INC. $3,597.75 11/10/2021 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792482403
Principal investigator 1 ABBVIE INC. $3,515.60 11/09/2021 Non-covered Recipient Entity
CLINRX RESEARCH LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792481961
Principal investigator 1 SANOFI US SERVICES INC. $11,800.00 11/08/2021 Non-covered Recipient Entity
Clinrx Research Joseph Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 838655655
Principal investigator 1 GlaxoSmithKline, LLC. $256.50 11/02/2021 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 860868793
Principal investigator 1 ABBVIE INC. $43.36 10/28/2021 Non-covered Recipient Entity
CLINRX RESEARCH LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792480619
Principal investigator 1 ABBVIE INC. $28,124.45 10/07/2021 Non-covered Recipient Entity
CLINRX RESEARCH LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792478225
Principal investigator 1 ABBVIE INC. $6,688.00 10/07/2021 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792478503
Principal investigator 1 ABBVIE INC. $90.20 09/23/2021 Non-covered Recipient Entity
CLINRX RESEARCH LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792476215
Principal investigator 1 ABBVIE INC. $984.15 09/23/2021 Non-covered Recipient Entity
CLINRX RESEARCH LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792476217
Principal investigator 1 ABBVIE INC. $48.65 09/23/2021 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792476285
Principal investigator 1 ABBVIE INC. $1,125.00 09/16/2021 Non-covered Recipient Entity
CLINRX RESEARCH LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792475767
Principal investigator 1 ABBVIE INC. $11,333.85 09/08/2021 Non-covered Recipient Entity
CLINRX RESEARCH LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792474415
Principal investigator 1 ABBVIE INC. $49.25 08/31/2021 Non-covered Recipient Entity
CLINRX RESEARCH LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792473583
Principal investigator 1 ABBVIE INC. $367.20 08/30/2021 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792473119
Principal investigator 1 ABBVIE INC. $75.00 08/19/2021 Non-covered Recipient Entity
CLINRX RESEARCH LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792472429
Principal investigator 1 ABBVIE INC. $1,920.45 08/19/2021 Non-covered Recipient Entity
CLINRX RESEARCH LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792472431
Principal investigator 1 ABBVIE INC. $52.04 08/12/2021 Non-covered Recipient Entity
CLINRX RESEARCH LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792472011
Principal investigator 1 ABBVIE INC. $13,343.75 07/29/2021 Non-covered Recipient Entity
CLINRX RESEARCH LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792469583
Principal investigator 1 ABBVIE INC. $3,087.80 07/29/2021 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792470001
Principal investigator 1 ABBVIE INC. $70.58 07/22/2021 Non-covered Recipient Entity
CLINRX RESEARCH LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792468409
Principal investigator 1 ABBVIE INC. $1,055.85 07/22/2021 Non-covered Recipient Entity
CLINRX RESEARCH LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792468411
Principal investigator 1 GlaxoSmithKline, LLC. $229.50 07/12/2021 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 809492587
Principal investigator 1 ABBVIE INC. $10,111.70 07/08/2021 Non-covered Recipient Entity
CLINRX RESEARCH LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792467025
Principal investigator 1 ABBVIE INC. $95.73 07/07/2021 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792466723
Principal investigator 1 ABBVIE INC. $150.00 07/07/2021 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792466725
Principal investigator 1 ABBVIE INC. $4,630.40 06/30/2021 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792465039
Principal investigator 1 ABBVIE INC. $371.81 06/28/2021 Non-covered Recipient Entity
CLINRX RESEARCH LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792464187
Principal investigator 1 ABBVIE INC. $480.00 06/25/2021 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792464145
Principal investigator 1 ABBVIE INC. $12,557.40 05/27/2021 Non-covered Recipient Entity
CLINRX RESEARCH LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792460323
Principal investigator 1 ABBVIE INC. $5,558.45 05/27/2021 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792460641
Principal investigator 1 ABBVIE INC. $526.50 05/20/2021 Non-covered Recipient Entity
CLINRX RESEARCH LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792458671
Principal investigator 1 ABBVIE INC. $3,400.40 05/05/2021 Non-covered Recipient Entity
CLINRX RESEARCH LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792453521
Principal investigator 1 ABBVIE INC. $392.00 04/29/2021 Non-covered Recipient Entity
CLINRX RESEARCH LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792448779
Principal investigator 1 ABBVIE INC. $15,761.80 04/29/2021 Non-covered Recipient Entity
CLINRX RESEARCH LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792448785
Principal investigator 1 ABBVIE INC. $3,121.15 04/29/2021 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792449689
Principal investigator 1 ABBVIE INC. $3,805.30 04/23/2021 Non-covered Recipient Entity
CLINRX RESEARCH LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792446959
Principal investigator 1 ABBVIE INC. $2,430.00 04/15/2021 Non-covered Recipient Entity
CLINRX RESEARCH LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792445429
Principal investigator 1 ABBVIE INC. $2,902.50 04/15/2021 Non-covered Recipient Entity
CLINRX RESEARCH LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792445435
Principal investigator 1 ABBVIE INC. $2,583.40 04/15/2021 Non-covered Recipient Entity
CLINRX RESEARCH LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792445441
Principal investigator 1 ABBVIE INC. $3,115.20 04/15/2021 Non-covered Recipient Entity
CLINRX RESEARCH LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792445447
Principal investigator 1 ABBVIE INC. $123.62 04/13/2021 Non-covered Recipient Entity
CLINRX RESEARCH LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792444763
Principal investigator 1 ABBVIE INC. $48.17 04/13/2021 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792444789
Principal investigator 1 ABBVIE INC. $2,302.05 04/08/2021 Non-covered Recipient Entity
CLINRX RESEARCH LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792443251
Principal investigator 1 ABBVIE INC. $3,518.25 04/08/2021 Non-covered Recipient Entity
CLINRX RESEARCH LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792443257
Principal investigator 1 ABBVIE INC. $1,684.80 04/06/2021 Non-covered Recipient Entity
CLINRX RESEARCH LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792442715
Principal investigator 1 ABBVIE INC. $4,843.80 04/06/2021 Non-covered Recipient Entity
CLINRX RESEARCH LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792442721
Principal investigator 1 ABBVIE INC. $867.75 03/30/2021 Non-covered Recipient Entity
CLINRX RESEARCH LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792436975
Principal investigator 1 ABBVIE INC. $2,463.65 03/30/2021 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792437731
Principal investigator 1 ABBVIE INC. $150.00 03/26/2021 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792435843
Principal investigator 1 ABBVIE INC. $350.00 03/26/2021 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792435847
Principal investigator 1 GlaxoSmithKline, LLC. $432.00 03/15/2021 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 809496511
Principal investigator 1 ABBVIE INC. $1,060.50 03/11/2021 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792433207
Principal investigator 1 ABBVIE INC. $14,158.55 03/02/2021 Non-covered Recipient Entity
CLINRX RESEARCH LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792427843
Principal investigator 1 ABBVIE INC. $3,154.85 03/02/2021 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792428979
Principal investigator 1 GlaxoSmithKline, LLC. $1,201.52 03/01/2021 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 809496507
Principal investigator 1 ABBVIE INC. $160.00 02/23/2021 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792425187
Principal investigator 1 ABBVIE INC. $3,796.55 02/04/2021 Non-covered Recipient Entity
CLINRX RESEARCH LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792420697
Principal investigator 1 ABBVIE INC. $150.00 02/01/2021 Non-covered Recipient Entity
CLINRX RESEARCH LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792419587
Principal investigator 1 ABBVIE INC. $19,031.60 01/28/2021 Non-covered Recipient Entity
CLINRX RESEARCH LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792414293
Principal investigator 1 ABBVIE INC. $2,417.85 01/28/2021 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792415367